Baxter supports analysis demonstrating clinical and economic benefits of effective intraoperative blood management for surgical patients

Deerfield, ill.--(business wire)--baxter international inc. (nyse:bax), a global leader in advancing surgical innovation, recognizes the findings of a large retrospective observational analysis published in the journal of medical economics. the baxter-sponsored analysis demonstrated that the use of active hemostatic products alone was associated with lower rates of bleeding-related complications, shorter hospital stays and reduced total hospital costs compared to combined use of passive and act
BAX Ratings Summary
BAX Quant Ranking